Expression levels of the cell adhesion marker L1CAM were measured with flow cytometry to determine early effects of pharmacological treatment on low-grade gliomagenesis, as L1CAM has been shown to be upregulated in IDH1R132H astrocytes [9], and in IDH1R132H glioma patients (source: CGGA). Here, L1CAM is linked to central nervous system cancer.